Oxford Nanopore at SNO 2026
:quality(80))
Overview
Oxford Nanopore are sponsoring, exhibiting and presenting for the first time at the Society of Neuro-Oncology (SNO) Annual Meeting 2026. The SNO Annual Meeting is the world’s largest neuro-oncology conference, regularly attracting more than 3,000 researchers and clinician scientists from over 40 countries. Spanning all neuro-oncology disciplines, professions, and interests, #SNO2026 will serve as the premier forum to share knowledge and gain insights into the future of neuro-oncology research and treatment.
Details for the Oxford Nanopore Independent Supported Symposia (ISS) is below.
Please also visit us at booth 32 if you are able to attend the conference.
ISS Session
Accelerating precision neuro-oncology with integrated methylation and molecular profiling
Comprehensive molecular characterization has become essential for the accurate classification and management of CNS tumors. This industry-sponsored session will showcase how rapid, real-time Oxford Nanopore sequencing is enabling comprehensive tumor methylation profiling and molecular characterization, delivering insights faster than ever before. The session will explore the opportunities and challenges of implementing integrated molecular sequencing workflows and discuss the future of comprehensive molecular diagnostics in precision neuro-oncology.
Date: Friday, November 13
Time: 6:00 pm-7:15 pm EST
Location: Room 115 C
Space is limited so be sure to register in advance. Please contact events@nanoporetech.com with any questions.
Ângela Serrano de Silva, PhD
:quality(80))
- Job title
- Institution
- Oxford Nanopore Technologies
Joachim Weischenfeldt, PhD
:quality(80))
- Job title
- Institution
- BRIC, University of Copenhagen
- Biography
Dr Weischenfeldt is a professor in oncology at BRIC, University of Copenhagen and Rigshospitalet, Denmark. His research aims to decode the mutational mechanisms driving cancer development, progression, and therapy resistance with a particular focus on genomic structural variations. By integrating computational and molecular genomics, his group aims to understand how genomic alterations shape clonal evolution and clinical outcomes
Bonnie L Cole, MD
- Job title
- Institution
- Seattle Children’s Hospital
